Amyloid plaques found in the brains of Alzheimer’s disease (AD) patients primarily consists of amyloid beta 1-42 (Ab42). Commercially, Ab42 is synthetized using peptide synthesizers. We describe a robust methodology for expression of recombinant human Ab(M1-42) in Rosetta(DE3)pLysS and BL21(DE3)pLysS competent E. coli with refined and rapid analytical purification techniques. The peptide is isolated and purified from the transformed cells using an optimized set-up for reverse-phase HPLC protocol, using commonly available C18 columns, yielding high amounts of peptide (~15-20 mg per 1 L culture) in a short time. The recombinant Ab(M1-42) forms characteristic aggregates similar to synthetic Ab42 aggregates as verified by western blots and atomic force microscopy to warrant future biological use. Our rapid, refined, and robust technique to purify human Ab(M1-42) can be used to synthesize chemical probes for several downstream in vitro and in vivo assays to facilitate AD research.
download asset Prakash_Lantz_etal_recAbeta_02-15-2019.pdf 13 MB [opens in a new tab] cloud_download
pdf : 13 MB
download asset Prakash_Lantz_etal_recAbeta_02-15-2019_Supporting.pdf 0.05 MB [opens in a new tab] cloud_download
pdf : 0.05 MB
Prakash Lantz etal recAbeta 02-15-2019 Supporting